Synlogic Inc (SYBX) Expected to Post Q1 2019 Earnings of ($0.51) Per Share
Synlogic Inc (NASDAQ:SYBX) – Analysts at Svb Leerink upped their Q1 2019 earnings estimates for shares of Synlogic in a report issued on Wednesday, March 13th. Svb Leerink analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.58). Svb Leerink also issued estimates for Synlogic’s Q2 2019 earnings at ($0.52) EPS, Q3 2019 earnings at ($0.54) EPS, Q4 2019 earnings at ($0.56) EPS, FY2019 earnings at ($2.13) EPS and FY2020 earnings at ($1.98) EPS.
Synlogic (NASDAQ:SYBX) last released its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. Synlogic had a negative net margin of 1,922.02% and a negative return on equity of 35.58%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.24 million.
Synlogic stock opened at $7.73 on Friday. Synlogic has a 52-week low of $5.75 and a 52-week high of $14.59. The company has a market cap of $197.99 million, a price-to-earnings ratio of -3.81 and a beta of 2.38.
In other news, insider Paul Francis Miller sold 9,000 shares of Synlogic stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $9.75, for a total value of $87,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 23.30% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Synlogic in the 3rd quarter valued at $33,000. American International Group Inc. acquired a new stake in Synlogic in the 3rd quarter valued at $145,000. Rhumbline Advisers grew its position in Synlogic by 45.7% in the 4th quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 6,820 shares during the period. TIAA CREF Investment Management LLC acquired a new stake in Synlogic in the 3rd quarter valued at $251,000. Finally, Fosun International Ltd acquired a new stake in Synlogic in the 4th quarter valued at $286,000. 84.85% of the stock is owned by institutional investors and hedge funds.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Read More: Technical Analysis
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.